Global Information
회사소개 | 문의 | 비교리스트

세계의 유효성 시험 시장 예측(-2027년) : 서비스 종류별(항균성/방부 효과 시험, 살균 효과 시험), 용도별(의약품 제조, 화장품과 퍼스널케어 제품, 의료기기, 소비자 제품), 지역별

Efficacy Testing Market by Service Type (Antimicrobial/Preservative Efficacy Testing, Disinfectant Efficacy Testing), Application (Pharma, Cosmetics & Personal Care, Medical Devices, Consumer Products) and Region - Global Forecast to 2027

리서치사 MarketsandMarkets
발행일 2022년 07월 상품코드 1105262
페이지 정보 영문 176 Pages 배송안내
가격
US $ 4,950 ₩ 6,529,000 PDF (Single User License) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 6,650 ₩ 8,772,000 PDF (5-user License) help
동일 사업장 내 5명까지 공유하여 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 8,150 ₩ 10,750,000 PDF (Corporate License) help
기업 내 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없지만, 동일 국가의 동일 사업장에 한정되며 해외지점 등은 포함되지 않습니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 10,000 ₩ 13,191,000 PDF (Global License) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없습니다. 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


세계의 유효성 시험 시장 예측(-2027년) : 서비스 종류별(항균성/방부 효과 시험, 살균 효과 시험), 용도별(의약품 제조, 화장품과 퍼스널케어 제품, 의료기기, 소비자 제품), 지역별 Efficacy Testing Market by Service Type (Antimicrobial/Preservative Efficacy Testing, Disinfectant Efficacy Testing), Application (Pharma, Cosmetics & Personal Care, Medical Devices, Consumer Products) and Region - Global Forecast to 2027
발행일 : 2022년 07월 페이지 정보 : 영문 176 Pages

본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

세계의 유효성 시험 시장 규모는 2022년 3억 1,500만 달러에서 2027년까지 4억 2,300만 달러에 달하고, 예측기간 중 CAGR로 6.1%의 성장이 예측됩니다.

이 시장 성장은 주로 의약품 제조, 바이오의약품, 화장품 업계에서 오염 방지와 제품 안정성을 위해 표면 살균제와 방부제 사용이 증가하고 있는 점, 유효성 시험 아웃소싱을 선호하는 경향이 높아지고 있는 점, QbD 어프로치 채용이 증가하고 있는 점에 기인하고 있습니다. 신흥 시장의 높은 성장성은 유효성 시험 시장에서 활동하는 기업에게 성장 기회를 생성할 것으로 예상됩니다.

"서비스 종류별로는 기존 시험이 항균성·방부 효과 시험 시장에서 최대의 점유율을 차지하고 있다"

기존 시험은 일반적으로 장기간에 걸친 다수의 시험 포인트에서의 미생물 어세이를 필요로 합니다. 시험 기간은 보통 최저 28일간에서 12주간 이상에 이릅니다. 더 장기의 일반적인 과제 프로토콜에서 채용되고 있는 것과 같은 표준적인 미생물학적 기술이 관여하고 있기 때문에, 어세이를 실시하기 위해서 특별한 설비나 트레이닝은 필요 없습니다.

"용도별로는 예측기간 중 의약품 제조 부문이 가장 높은 성장률을 나타내 보인다"

2021년 의약품 제조 용도는 시장에서 최대 제품 부문이었습니다. 이 시장 성장은 대형 제약회사에 의한 연구개발 제조 증가, 정부 지원, 제약 업계 성장, 환자 안전성에 대한 주목 상승에 기인할 것으로 생각됩니다.

"아시아태평양 시장은 예측기간(2020-2027년)에 가장 높은 성장률을 나타낼 것으로 예측된다"

아시아태평양 시장은 예측기간 중 가장 높은 CAGR로 성장할 것으로 예측됩니다. 이것은 주로 헬스케어에 대한 정부 지출 증가, 노인 인구 증가, 소비자의 건강 인식 확산, 만성질환 발생률 증가에 의해 이 지역 의약품의 성장 원인이 되고 있는 점, APAC 국가에서 제조 시설을 설립하는 제약회사 수가 증가하고 있는 점에 기인하고 있습니다.

"북미 : 유효성 시험 시장 최대 점유율"

이 지역에는 확립된 제약 업계가 존재하고, 높은 연구개발비, 주요 서비스 프로바이더의 존재감, 이 지역의 제약회사나 화장품 회사에 의한 분석 시험(유효성 시험을 포함) 아웃소싱 증가 등의 요인이 시장 성장의 주요인입니다.

목차

제1장 서론

제2장 조사 방법

제3장 주요 요약

제4장 주요 인사이트

제5장 시장 개요

  • 서론
  • 시장 역학
    • 성장 촉진요인
    • 성장 억제요인
    • 기회
    • 과제
  • 규제 분석
  • 유효성 시험 서비스에 대한 COVID-19의 영향
  • 가격 분석
  • 특허 분석
  • 무역 분석
  • 밸류체인 분석
  • 생태계 분석
  • Porter's Five Forces 분석
  • 기술 분석

제6장 유효성 시험 시장 : 서비스 종류별

  • 서론
  • 살균 효과 시험
    • 표면 시험
    • 현탁 시험
  • 항균성·방부 효과 시험
    • 기존
    • 신속형

제7장 유효성 시험 시장 : 용도별

  • 서론
  • 의약품 제조
  • 화장품·퍼스널케어 제품
  • 소비자 제품
  • 의료기기

제8장 유효성 시험 시장 : 지역별

  • 서론
  • 북미
    • 미국
    • 캐나다
  • 유럽
    • 독일
    • 프랑스
    • 영국
    • 이탈리아
    • 스페인
    • 기타
  • 아시아태평양
    • 중국
    • 일본
    • 인도
    • 기타
  • 기타 지역
    • 라틴아메리카
    • 중동 및 아프리카

제9장 경쟁 상황

  • 개요
  • 주요 기업 전략/유력 기업
  • 시장 점유율 분석
  • 주요 시장 기업의 매출 점유율 분석
  • 기업 평가 상한
  • 기업 평가 상한 : 스타트업/중소기업
  • 기업 발자국 분석
  • 경쟁 시나리오

제10장 기업 개요

  • 유효성 시험 서비스 프로바이더
    • EUROFINS SCIENTIFIC
    • CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
    • WUXI APPTEC
    • SGS SA
    • INTERTEK GROUP PLC
    • MICROCHEM LABORATORY
    • ACCUGEN LABORATORIES, INC.
    • PACIFIC BIOLABS
    • NORTH AMERICAN SCIENCE ASSOCIATES
    • TOXIKON
    • BIOSCIENCE LABORATORIES, INC.
    • CONSUMER PRODUCT TESTING COMPANY(CPTC)
    • ALMAC GROUP
    • MSL SOLUTION PROVIDERS
    • NELSON LABORATORIES, LLC(A SOTERA HEALTH COMPANY)
    • ALS LIMITED
    • ABBOTT ANALYTICAL
    • BLUTEST LABORATORIES LIMITED
    • LUCIDEON
    • HELVIC LABORATORIES(A TENTAMUS COMPANY)
  • 살균제 제조업체
    • PROCTER & GAMBLE
    • THE CLOROX COMPANY
    • 3M
    • RECKITT BENCKISER GROUP PLC
    • ECOLAB
    • STERIS
    • CANTEL MEDICAL
    • DIVERSEY HOLDINGS LTD.
    • CARROLLCLEAN
    • PAUL HARTMANN AG

제11장 부록

KSM 22.08.05

The global efficacy testing market is projected to reach USD 423 million by 2027 from USD 315 million in 2022, at a CAGR of 6.1% during the forecast period. The growth of this market is mainly driven by the increasing use of surface disinfectants and preservatives in pharma, biopharma, and cosmetics industries for contamination control and product stability; growing preference for outsourcing efficacy testing; and the rising adoption of the QbD approach. The high growth potential in emerging markets will provide growth opportunities for players operating in the efficacy testing market.

"By method type, the traditional test method accounted for the largest share of the antimicrobial/preservative testing market"

Traditional testing methods generally require microbial assays at multiple test points over extended periods of time. Test durations typically range from a minimum of 28 days to 12 or more weeks. Because standard microbiological techniques similar to those employed in longer-term generic challenge protocols are involved, no special equipment or training is necessary to perform the assay. In fact, this accelerated double challenge (ADC) assay is currently being used in its basic form or in variations at numerous laboratories for a variety of applications.

"The pharmaceutical manufacturing application segment will grow at the highest rate during the forecast period."

On the basis of application, the efficacy testing market is segmented into pharmaceutical manufacturing applications, cosmetics and personal care product applications, consumer product applications, and medical device applications. In 2021, pharmaceutical manufacturing applications were the largest product segment in the market. Growth in this market can be attributed to the increasing R&D manufactures by leading pharmaceutical companies, government support, growth of the pharmaceutical industry, and a growing focus on patient safety.

"The market in the Asia Pacific is projected to witness the highest growth rate during the forecast period (2020-2027)."

The Asia Pacific market is projected to grow at the highest CAGR during the forecast period, mainly due to the increasing government expenditure on healthcare, rising geriatric population, growing consumer health awareness, increasing incidence of chronic diseases thereby being responsible for the growth of pharmaceutical products in this region, and the increasing number of pharmaceutical companies that are establishing manufacturing facilities in APAC countries.

"North America: the largest share of the efficacy testing market"

North America accounted for the largest share of the efficacy testing market. Factors such as the presence of a well established pharmaceutical industry in the region, the high R&D expenditure, a strong presence of major service providers, and rising outsourcing of analytical testing (including efficacy testing) by pharmaceutical and cosmetic companies in the region are the major factors driving the market growth.

Breakdown of primaries

The study contains insights from various industry experts, ranging from component suppliers to Tier 1 companies and OEMs. The break-up of the primaries is as follows:

  • By Respondent- Supply Side- 80%, Demand Side-20%
  • By Designation- Executives- 25%, CXOs- 20%, Managers - 55%
  • By Region- North America - 50%, Europe - 20%, APAC - 20%, RoW- 10%

The key players operating in the efficacy testing market are Charles River Laboratories (US), WuXi AppTec (China), Eurofins Scientific (Luxembourg), SGS (Switzerland), Intertek Group (UK), Nelson Laboratories, LLC (a Sotera Health company, US), Microbac Laboratories, Inc. (US), Almac Group (UK), North American Science Associates, Inc. (US), Toxikon (US), Pacific Biolabs (US), MSL Solution Providers (UK), Intertek Group PLC (UK), Accugen Laboratories, Inc. (US), Consumer Product Testing Company (US), Lucideon (UK), BioScience Laboratories, Inc. (US), ALS Limited (Australia), Microchem Laboratory (US), Oxford Biosciences Ltd. (UK), Abbott Analytical (Australia), Helvic Laboratories (a Tentamus Company, UK), Honeyman Group Limited (UK), Danish Technological Institute (DTI, Denmark), and BluTest Laboratories Limited (UK).

Research Coverage:

The report segments the efficacy testing market based on region (Asia Pacific, Europe, North America, and RoW), service type (disinfectant efficacy testing and antimicrobial/preservative efficacy testing), application (pharmaceutical manufacturing applications, cosmetics and personal care product applications, consumer product applications, and medical device applications).

The report also provides a comprehensive review of market drivers, challenges, and opportunities in the efficacy testing market

Key Benefits of Buying the Report:

The report will help the leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall market and the sub-segments. This report will help stakeholders understand the competitive landscape and gain more insights to better position their businesses and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the efficacy testing market and provides them information on key market drivers, challenges, and opportunities.

This report provides insights into the following pointers:

  • Market Penetration: Comprehensive information on the product portfolios of the top players in the efficacy testing market. The report analyzes the market based on the service type, application, and region.
  • Service Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and service/product launches in the efficacy testing market.
  • Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various types of efficacy testing solutions across regions.
  • Market Diversification: Exhaustive information about products/ services, untapped regions, recent developments, and investments in the efficacy testing market.
  • Competitive Assessment: In-depth assessment of market shares, strategies, products, distribution networks, and manufacturing capabilities of the leading players in the efficacy testing market.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
    • 1.2.1 INCLUSIONS AND EXCLUSIONS
  • 1.3 MARKET SCOPE
    • 1.3.1 MARKETS COVERED
    • 1.3.2 YEARS CONSIDERED
  • 1.4 CURRENCY
  • 1.5 LIMITATIONS
  • 1.6 STAKEHOLDERS
  • 1.7 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH APPROACH
    • 2.1.1 SECONDARY DATA
    • 2.1.2 PRIMARY DATA
      • 2.1.2.1 Breakdown of primary sources
    • FIGURE 1 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
      • 2.1.2.2 Key industry insights
  • 2.2 MARKET SIZE ESTIMATION
    • FIGURE 2 MARKET SIZE ESTIMATION: SUPPLY-SIDE ANALYSIS
    • FIGURE 3 EFFICACY TESTING MARKET: FINAL CAGR PROJECTIONS
    • FIGURE 4 EFFICACY TESTING MARKET: CAGR PROJECTIONS FROM ANALYSIS OF DEMAND-SIDE DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
    • FIGURE 5 EFFICACY TESTING MARKET: SEGMENTAL ASSESSMENT
  • 2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
    • FIGURE 6 DATA TRIANGULATION METHODOLOGY
  • 2.4 MARKET RANKING ANALYSIS
  • 2.5 RESEARCH ASSUMPTIONS

3 EXECUTIVE SUMMARY

    • FIGURE 7 EFFICACY TESTING MARKET, BY SERVICE TYPE, 2022 VS. 2027 (USD MILLION)
    • FIGURE 8 EFFICACY TESTING MARKET, BY APPLICATION, 2022 VS. 2027 (USD MILLION)
    • FIGURE 9 REGIONAL SNAPSHOT OF EFFICACY TESTING MARKET

4 PREMIUM INSIGHTS

  • 4.1 EFFICACY TESTING MARKET OVERVIEW
    • FIGURE 10 GROWING PREFERENCE FOR OUTSOURCING EFFICACY TESTING TO DRIVE MARKET GROWTH
  • 4.2 ASIA PACIFIC: EFFICACY TESTING MARKET, BY APPLICATION AND COUNTRY (2021)
    • FIGURE 11 PHARMACEUTICAL MANUFACTURING APPLICATIONS SEGMENT ACCOUNTED FOR LARGEST SHARE OF ASIA PACIFIC MARKET IN 2021
  • 4.3 GEOGRAPHICAL SNAPSHOT OF EFFICACY TESTING MARKET
    • FIGURE 12 CHINA TO WITNESS HIGHEST GROWTH RATE FROM 2022 TO 2027
  • 4.4 EFFICACY TESTING MARKET, BY REGION
    • FIGURE 13 NORTH AMERICA TO DOMINATE MARKET IN 2027
  • 4.5 EFFICACY TESTING MARKET: DEVELOPED VS. DEVELOPING MARKETS
    • FIGURE 14 DEVELOPING MARKETS TO REGISTER HIGHER GROWTH RATE DURING FORECAST PERIOD

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • FIGURE 15 EFFICACY TESTING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
    • 5.2.1 DRIVERS
      • 5.2.1.1 Increasing use of surface disinfectants and preservatives in pharma, biopharma, and cosmetics industries for contamination control and product stability
        • 5.2.1.1.1 Growing focus on contamination control
        • 5.2.1.1.2 Increasing concerns over product stability
      • 5.2.1.2 Growing preference for outsourcing efficacy testing
      • 5.2.1.3 Rising adoption of quality by design approach
      • 5.2.1.4 Stringent regulations for use of surface disinfectants
      • 5.2.1.5 Growing awareness of sanitization and hygiene due to spread of COVID-19
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 Adverse effects of chemical disinfectants
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Emerging countries in Asia Pacific
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Time-consuming process
  • 5.3 REGULATORY ANALYSIS
    • 5.3.1 DISINFECTANT EFFICACY TESTING
    • 5.3.2 ANTIMICROBIAL EFFICACY TESTING
  • 5.4 IMPACT OF COVID-19 ON EFFICACY TESTING SERVICES
  • 5.5 PRICING ANALYSIS
    • TABLE 1 PRICE OF SURFACE DISINFECTANT PRODUCTS (2022)
  • 5.6 PATENT ANALYSIS
  • 5.7 TRADE ANALYSIS
    • 5.7.1 TRADE ANALYSIS FOR DISINFECTANTS
    • TABLE 2 IMPORT DATA FOR DISINFECTANTS, BY COUNTRY, 2018-2022 (USD MILLION)
    • TABLE 3 EXPORT DATA FOR DISINFECTANTS, BY COUNTRY, 2018-2022 (USD MILLION)
  • 5.8 VALUE CHAIN ANALYSIS
    • FIGURE 16 VALUE CHAIN ANALYSIS: EFFICACY TESTING MARKET
  • 5.9 ECOSYSTEM ANALYSIS
    • FIGURE 17 SURFACE DISINFECTANTS MARKET: ECOSYSTEM ANALYSIS
    • TABLE 4 ROLE IN ECOSYSTEM
  • 5.10 PORTER'S FIVE FORCES ANALYSIS
    • TABLE 5 EFFICACY TESTING MARKET: PORTER'S FIVE FORCES ANALYSIS
    • 5.10.1 THREAT OF NEW ENTRANTS
    • 5.10.2 THREAT OF SUBSTITUTES
    • 5.10.3 BARGAINING POWER OF BUYERS
    • 5.10.4 BARGAINING POWER OF SUPPLIERS
    • 5.10.5 DEGREE OF COMPETITION
  • 5.11 TECHNOLOGY ANALYSIS

6 EFFICACY TESTING MARKET, BY SERVICE TYPE

  • 6.1 INTRODUCTION
    • TABLE 6 EFFICACY TESTING MARKET, BY SERVICE TYPE, 2020-2027 (USD MILLION)
  • 6.2 DISINFECTANT EFFICACY TESTING
    • TABLE 7 DISINFECTANT EFFICACY TESTING MARKET, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 8 NORTH AMERICA: DISINFECTANT EFFICACY TESTING MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 9 EUROPE: DISINFECTANT EFFICACY TESTING MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 10 APAC: DISINFECTANT EFFICACY TESTING MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 11 ROW: DISINFECTANT EFFICACY TESTING MARKET, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 12 DISINFECTANT EFFICACY TESTING MARKET, BY METHOD, 2020-2027 (USD MILLION)
    • 6.2.1 SURFACE TEST METHOD
      • 6.2.1.1 Surface test method segment to account for larger share of disinfectant efficacy testing market
    • TABLE 13 SURFACE TEST METHOD MARKET, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 14 NORTH AMERICA: SURFACE TEST METHOD MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 15 EUROPE: SURFACE TEST METHOD MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 16 APAC: SURFACE TEST METHOD MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • 6.2.2 SUSPENSION TEST METHOD
      • 6.2.2.1 Suspension test method is typically performed by researchers during development stage of disinfectants
    • TABLE 17 SUSPENSION TEST METHOD MARKET, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 18 NORTH AMERICA: SUSPENSION TEST METHOD MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 19 EUROPE: SUSPENSION TEST METHOD MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 20 APAC: SUSPENSION TEST METHOD MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
  • 6.3 ANTIMICROBIAL/PRESERVATIVE EFFICACY TESTING
    • TABLE 21 EUROFINS SCIENTIFIC AET TEST PROTOCOL
    • TABLE 22 ANTIMICROBIAL/PRESERVATIVE EFFICACY TESTING MARKET, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 23 NORTH AMERICA: ANTIMICROBIAL/PRESERVATIVE EFFICACY TESTING MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 24 EUROPE: ANTIMICROBIAL/PRESERVATIVE EFFICACY TESTING MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 25 APAC: ANTIMICROBIAL/PRESERVATIVE EFFICACY TESTING MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 26 ROW: ANTIMICROBIAL/PRESERVATIVE EFFICACY TESTING MARKET, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 27 ANTIMICROBIAL/PRESERVATIVE EFFICACY TESTING MARKET, BY METHOD, 2020-2027 (USD MILLION)
    • 6.3.1 TRADITIONAL TEST METHOD
      • 6.3.1.1 Traditional test method segment to dominate AET/PET market
    • TABLE 28 TRADITIONAL TEST METHOD MARKET, BY REGION, 2020-2027 (USD MILLION)
    • 6.3.2 RAPID TEST METHOD
      • 6.3.2.1 Regulatory uncertainties restraining adoption of rapid microbial methods
    • TABLE 29 RAPID TEST METHOD MARKET, BY REGION, 2020-2027 (USD MILLION)

7 EFFICACY TESTING MARKET, BY APPLICATION

  • 7.1 INTRODUCTION
    • TABLE 30 EFFICACY TESTING MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
  • 7.2 PHARMACEUTICAL MANUFACTURING APPLICATIONS
    • 7.2.1 INCREASING FOCUS ON ENSURING QUALITY OF DRUGS TO DRIVE SEGMENT GROWTH
    • TABLE 31 EFFICACY TESTING MARKET FOR PHARMACEUTICAL MANUFACTURING APPLICATIONS, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 32 NORTH AMERICA: EFFICACY TESTING MARKET FOR PHARMACEUTICAL MANUFACTURING APPLICATIONS, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 33 EUROPE: EFFICACY TESTING MARKET FOR PHARMACEUTICAL MANUFACTURING APPLICATIONS, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 34 APAC: EFFICACY TESTING MARKET FOR PHARMACEUTICAL MANUFACTURING APPLICATIONS, BY COUNTRY, 2020-2027 (USD MILLION)
  • 7.3 COSMETICS AND PERSONAL CARE PRODUCT APPLICATIONS
    • 7.3.1 EFFICACY TESTING IS AN ESSENTIAL PART OF STABILITY TESTING REGIMEN OF COSMETICS
    • TABLE 35 EFFICACY TESTING MARKET FOR COSMETICS AND PERSONAL CARE PRODUCT APPLICATIONS, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 36 NORTH AMERICA: EFFICACY TESTING MARKET FOR COSMETICS AND PERSONAL CARE PRODUCT APPLICATIONS, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 37 EUROPE: EFFICACY TESTING MARKET FOR COSMETICS AND PERSONAL CARE PRODUCT APPLICATIONS, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 38 APAC: EFFICACY TESTING MARKET FOR COSMETICS AND PERSONAL CARE PRODUCT APPLICATIONS, BY COUNTRY, 2020-2027 (USD MILLION)
  • 7.4 CONSUMER PRODUCT APPLICATIONS
    • 7.4.1 GROWING FOCUS ON HEALTHY ENVIRONMENT IN HOMES AND INDUSTRIAL FACILITIES TO DRIVE SEGMENT GROWTH
    • TABLE 39 EFFICACY TESTING MARKET FOR CONSUMER PRODUCT APPLICATIONS, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 40 NORTH AMERICA: EFFICACY TESTING MARKET FOR CONSUMER PRODUCT APPLICATIONS, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 41 EUROPE: EFFICACY TESTING MARKET FOR CONSUMER PRODUCT APPLICATIONS, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 42 APAC: EFFICACY TESTING MARKET FOR CONSUMER PRODUCT APPLICATIONS, BY COUNTRY, 2020-2027 (USD MILLION)
  • 7.5 MEDICAL DEVICE APPLICATIONS
    • 7.5.1 IMPOSITION OF STRINGENT GOVERNMENT REGULATIONS TO DRIVE SEGMENT GROWTH
    • TABLE 43 EFFICACY TESTING MARKET FOR MEDICAL DEVICE APPLICATIONS, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 44 NORTH AMERICA: EFFICACY TESTING MARKET FOR MEDICAL DEVICE APPLICATIONS, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 45 EUROPE: EFFICACY TESTING MARKET FOR MEDICAL DEVICE APPLICATIONS, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 46 APAC: EFFICACY TESTING MARKET FOR MEDICAL DEVICE APPLICATIONS, BY COUNTRY, 2020-2027 (USD MILLION)

8 EFFICACY TESTING MARKET, BY REGION

  • 8.1 INTRODUCTION
    • TABLE 47 EFFICACY TESTING MARKET, BY REGION, 2020-2027 (USD MILLION)
  • 8.2 NORTH AMERICA
    • FIGURE 18 NORTH AMERICA: EFFICACY TESTING MARKET SNAPSHOT
    • TABLE 48 NORTH AMERICA: EFFICACY TESTING MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 49 NORTH AMERICA: EFFICACY TESTING MARKET, BY SERVICE TYPE, 2020-2027 (USD MILLION)
    • TABLE 50 NORTH AMERICA: DISINFECTANT EFFICACY TESTING MARKET, BY METHOD, 2020-2027 (USD MILLION)
    • TABLE 51 NORTH AMERICA: ANTIMICROBIAL/PRESERVATIVE EFFICACY TESTING MARKET, BY METHOD, 2020-2027 (USD MILLION)
    • TABLE 52 NORTH AMERICA: EFFICACY TESTING MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • 8.2.1 US
      • 8.2.1.1 US to dominate North American efficacy testing market during forecast period
    • TABLE 53 US: EFFICACY TESTING MARKET, BY SERVICE TYPE, 2020-2027 (USD MILLION)
    • TABLE 54 US: DISINFECTANT EFFICACY TESTING MARKET, BY METHOD, 2020-2027 (USD MILLION)
    • TABLE 55 US: EFFICACY TESTING MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • 8.2.2 CANADA
      • 8.2.2.1 Government initiatives to drive market growth in Canada
    • TABLE 56 CANADA: EFFICACY TESTING MARKET, BY SERVICE TYPE, 2020-2027 (USD MILLION)
    • TABLE 57 CANADA: DISINFECTANT EFFICACY TESTING MARKET, BY METHOD, 2020-2027 (USD MILLION)
    • TABLE 58 CANADA: EFFICACY TESTING MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
  • 8.3 EUROPE
    • TABLE 59 EUROPE: EFFICACY TESTING MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 60 EUROPE: EFFICACY TESTING MARKET, BY SERVICE TYPE, 2020-2027 (USD MILLION)
    • TABLE 61 EUROPE: DISINFECTANT EFFICACY TESTING MARKET, BY METHOD, 2020-2027 (USD MILLION)
    • TABLE 62 EUROPE: ANTIMICROBIAL/PRESERVATIVE EFFICACY TESTING MARKET, BY METHOD, 2020-2027 (USD MILLION)
    • TABLE 63 EUROPE: EFFICACY TESTING MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • 8.3.1 GERMANY
      • 8.3.1.1 Germany to account for largest share in European market
    • TABLE 64 GERMANY: EFFICACY TESTING MARKET, BY SERVICE TYPE, 2020-2027 (USD MILLION)
    • TABLE 65 GERMANY: DISINFECTANT EFFICACY TESTING MARKET, BY METHOD, 2020-2027 (USD MILLION)
    • TABLE 66 GERMANY: EFFICACY TESTING MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • 8.3.2 FRANCE
      • 8.3.2.1 High demand for cosmetics in France to drive market growth
    • TABLE 67 FRANCE: EFFICACY TESTING MARKET, BY SERVICE TYPE, 2020-2027 (USD MILLION)
    • TABLE 68 FRANCE: DISINFECTANT EFFICACY TESTING MARKET, BY METHOD, 2020-2027 (USD MILLION)
    • TABLE 69 FRANCE: EFFICACY TESTING MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • 8.3.3 UK
      • 8.3.3.1 Efficacy testing market in UK is primarily driven by enforcement of regulatory and industry standards
    • TABLE 70 UK: EFFICACY TESTING MARKET, BY SERVICE TYPE, 2020-2027 (USD MILLION)
    • TABLE 71 UK: DISINFECTANT EFFICACY TESTING MARKET, BY METHOD, 2020-2027 (USD MILLION)
    • TABLE 72 UK: EFFICACY TESTING MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • 8.3.4 ITALY
      • 8.3.4.1 Increasing pharmaceutical production in Italy to drive market growth
    • TABLE 73 ITALY: EFFICACY TESTING MARKET, BY SERVICE TYPE, 2020-2027 (USD MILLION)
    • TABLE 74 ITALY: DISINFECTANT EFFICACY TESTING MARKET, BY METHOD, 2020-2027 (USD MILLION)
    • TABLE 75 ITALY: EFFICACY TESTING MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • 8.3.5 SPAIN
      • 8.3.5.1 Rising R&D expenditure to boost market growth in Spain
    • TABLE 76 SPAIN: EFFICACY TESTING MARKET, BY SERVICE TYPE, 2020-2027 (USD MILLION)
    • TABLE 77 SPAIN: DISINFECTANT EFFICACY TESTING MARKET, BY METHOD, 2020-2027 (USD MILLION)
    • TABLE 78 SPAIN: EFFICACY TESTING MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • 8.3.6 REST OF EUROPE
    • TABLE 79 ROE: EFFICACY TESTING MARKET, BY SERVICE TYPE, 2020-2027 (USD MILLION)
    • TABLE 80 ROE: DISINFECTANT EFFICACY TESTING MARKET, BY METHOD, 2020-2027 (USD MILLION)
    • TABLE 81 ROE: EFFICACY TESTING MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
  • 8.4 ASIA PACIFIC
    • FIGURE 19 ASIA PACIFIC: EFFICACY TESTING MARKET SNAPSHOT
    • TABLE 82 APAC: EFFICACY TESTING MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 83 APAC: EFFICACY TESTING MARKET, BY SERVICE TYPE, 2020-2027 (USD MILLION)
    • TABLE 84 APAC: DISINFECTANT EFFICACY TESTING MARKET, BY METHOD, 2020-2027 (USD MILLION)
    • TABLE 85 APAC: ANTIMICROBIAL/PRESERVATIVE EFFICACY TESTING MARKET, BY METHOD, 2020-2027 (USD MILLION)
    • TABLE 86 APAC: EFFICACY TESTING MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • 8.4.1 CHINA
      • 8.4.1.1 China to dominate Asia Pacific market
    • TABLE 87 CHINA: EFFICACY TESTING MARKET, BY SERVICE TYPE, 2020-2027 (USD MILLION)
    • TABLE 88 CHINA: DISINFECTANT EFFICACY TESTING MARKET, BY METHOD, 2020-2027 (USD MILLION)
    • TABLE 89 CHINA: EFFICACY TESTING MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • 8.4.2 JAPAN
      • 8.4.2.1 Rising R&D investments to drive market growth in Japan
    • TABLE 90 JAPAN: EFFICACY TESTING MARKET, BY SERVICE TYPE, 2020-2027 (USD MILLION)
    • TABLE 91 JAPAN: DISINFECTANT EFFICACY TESTING MARKET, BY METHOD, 2020-2027 (USD MILLION)
    • TABLE 92 JAPAN: EFFICACY TESTING MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • 8.4.3 INDIA
      • 8.4.3.1 Growing pharmaceutical industry in India to drive market growth
    • TABLE 93 INDIA: EFFICACY TESTING MARKET, BY SERVICE TYPE, 2020-2027 (USD MILLION)
    • TABLE 94 INDIA: DISINFECTANT EFFICACY TESTING MARKET, BY METHOD, 2020-2027 (USD MILLION)
    • TABLE 95 INDIA: EFFICACY TESTING MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • 8.4.4 REST OF ASIA PACIFIC
    • TABLE 96 ROAPAC: EFFICACY TESTING MARKET, BY SERVICE TYPE, 2020-2027 (USD MILLION)
    • TABLE 97 ROAPAC: DISINFECTANT EFFICACY TESTING MARKET, BY METHOD, 2020-2027 (USD MILLION)
    • TABLE 98 ROAPAC: EFFICACY TESTING MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
  • 8.5 REST OF THE WORLD
    • TABLE 99 ROW: EFFICACY TESTING MARKET, BY SERVICE TYPE, 2020-2027 (USD MILLION)
    • TABLE 100 ROW: DISINFECTANT EFFICACY TESTING MARKET, BY METHOD, 2020-2027 (USD MILLION)
    • TABLE 101 ROW: ANTIMICROBIAL/PRESERVATIVE EFFICACY TESTING MARKET, BY METHOD, 2020-2027 (USD MILLION)
    • TABLE 102 ROW: EFFICACY TESTING MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 103 ROW: EFFICACY TESTING MARKET, BY REGION, 2020-2027 (USD MILLION)
    • 8.5.1 LATIN AMERICA
      • 8.5.1.1 Increasing pharmaceutical R&D expenditure to drive market growth in Latin America
    • TABLE 104 LATAM: EFFICACY TESTING MARKET, BY SERVICE TYPE, 2020-2027 (USD MILLION)
    • TABLE 105 LATAM: EFFICACY TESTING MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • 8.5.2 MIDDLE EAST AND AFRICA
      • 8.5.2.1 UAE has emerged as key market in MEA region
    • TABLE 106 MEA: EFFICACY TESTING MARKET, BY SERVICE TYPE, 2020-2027 (USD MILLION)
    • TABLE 107 MEA: EFFICACY TESTING MARKET, BY APPLICATION, 2020-2027 (USD MILLION)

9 COMPETITIVE LANDSCAPE

  • 9.1 OVERVIEW
  • 9.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
    • FIGURE 20 KEY DEVELOPMENTS IN EFFICACY TESTING MARKET, 2019-2022
  • 9.3 MARKET SHARE ANALYSIS
    • FIGURE 21 EFFICACY TESTING MARKET SHARE, BY KEY PLAYER, 2021
    • TABLE 108 EFFICACY TESTING MARKET: DEGREE OF COMPETITION
  • 9.4 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS
  • 9.5 COMPANY EVALUATION QUADRANT
    • 9.5.1 STARS
    • 9.5.2 EMERGING LEADERS
    • 9.5.3 PERVASIVE PLAYERS
    • 9.5.4 PARTICIPANTS
  • 9.6 COMPANY EVALUATION QUADRANT: START-UPS/SMES
    • 9.6.1 PROGRESSIVE COMPANIES
    • 9.6.2 STARTING BLOCKS
    • 9.6.3 RESPONSIVE COMPANIES
    • 9.6.4 DYNAMIC COMPANIES
  • 9.7 FOOTPRINT ANALYSIS OF COMPANIES
    • 9.7.1 SERVICE FOOTPRINT OF COMPANIES
    • TABLE 109 SERVICE FOOTPRINT OF COMPANIES: EFFICACY TESTING MARKET (2021)
    • 9.7.2 REGIONAL FOOTPRINT OF COMPANIES
    • TABLE 110 REGIONAL FOOTPRINT OF COMPANIES: EFFICACY TESTING MARKET (2021)
  • 9.8 COMPETITIVE SCENARIO
    • TABLE 111 PRODUCT LAUNCHES
    • TABLE 112 DEALS
    • TABLE 113 OTHER DEVELOPMENTS

10 COMPANY PROFILES

  • 10.1 EFFICACY TESTING SERVICE PROVIDERS
  • (Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))**
    • 10.1.1 EUROFINS SCIENTIFIC
    • TABLE 114 EUROFINS SCIENTIFIC: BUSINESS OVERVIEW
    • FIGURE 25 EUROFINS SCIENTIFIC: COMPANY SNAPSHOT (2021)
    • 10.1.2 CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
    • TABLE 115 CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: BUSINESS OVERVIEW
    • FIGURE 26 CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: COMPANY SNAPSHOT (2021)
    • 10.1.3 WUXI APPTEC
    • TABLE 116 WUXI APPTEC: BUSINESS OVERVIEW
    • FIGURE 27 WUXI APPTEC: COMPANY SNAPSHOT (2021)
    • 10.1.4 SGS SA
    • TABLE 117 SGS SA: BUSINESS OVERVIEW
    • 10.1.5 INTERTEK GROUP PLC
    • TABLE 118 INTERTEK GROUP PLC: BUSINESS OVERVIEW
    • FIGURE 28 INTERTEK GROUP PLC: COMPANY SNAPSHOT (2021)
    • 10.1.6 MICROCHEM LABORATORY
    • TABLE 119 MICROCHEM LABORATORY: BUSINESS OVERVIEW
    • 10.1.7 ACCUGEN LABORATORIES, INC.
    • TABLE 120 ACCUGEN LABORATORIES, INC.: BUSINESS OVERVIEW
    • 10.1.8 PACIFIC BIOLABS
    • TABLE 121 PACIFIC BIOLABS: BUSINESS OVERVIEW
    • 10.1.9 NORTH AMERICAN SCIENCE ASSOCIATES
    • TABLE 122 NORTH AMERICAN SCIENCE ASSOCIATES: BUSINESS OVERVIEW
    • 10.1.10 TOXIKON
    • TABLE 123 TOXIKON: BUSINESS OVERVIEW
    • 10.1.11 BIOSCIENCE LABORATORIES, INC.
    • TABLE 124 BIOSCIENCE LABORATORIES, INC.: BUSINESS OVERVIEW
    • 10.1.12 CONSUMER PRODUCT TESTING COMPANY (CPTC)
    • TABLE 125 CONSUMER PRODUCT TESTING COMPANY (CPTC): BUSINESS OVERVIEW
    • 10.1.13 ALMAC GROUP
    • TABLE 126 ALMAC GROUP: BUSINESS OVERVIEW
    • 10.1.14 MSL SOLUTION PROVIDERS
    • TABLE 127 MSL SOLUTION PROVIDERS: BUSINESS OVERVIEW
    • 10.1.15 NELSON LABORATORIES, LLC (A SOTERA HEALTH COMPANY)
    • TABLE 128 NELSON LABORATORIES, LLC: BUSINESS OVERVIEW
    • 10.1.16 ALS LIMITED
    • TABLE 129 ALS LIMITED: BUSINESS OVERVIEW
    • 10.1.17 ABBOTT ANALYTICAL
    • TABLE 130 ABBOTT ANALYTICAL: BUSINESS OVERVIEW
    • 10.1.18 BLUTEST LABORATORIES LIMITED
    • TABLE 131 BLUTEST LABORATORIES LIMITED: BUSINESS OVERVIEW
    • 10.1.19 LUCIDEON
    • TABLE 132 LUCIDEON: BUSINESS OVERVIEW
    • 10.1.20 HELVIC LABORATORIES (A TENTAMUS COMPANY)
    • TABLE 133 HELVIC LABORATORIES: BUSINESS OVERVIEW
  • 10.2 MANUFACTURERS OF DISINFECTANTS
    • 10.2.1 PROCTER & GAMBLE
    • TABLE 134 PROCTER & GAMBLE: BUSINESS OVERVIEW
    • FIGURE 29 PROCTER & GAMBLE: COMPANY SNAPSHOT (2021)
    • 10.2.2 THE CLOROX COMPANY
    • TABLE 135 THE CLOROX COMPANY: BUSINESS OVERVIEW
    • FIGURE 30 THE CLOROX COMPANY: COMPANY SNAPSHOT (2021)
    • 10.2.3 3M
    • TABLE 136 3M: BUSINESS OVERVIEW
    • FIGURE 31 3M: COMPANY SNAPSHOT (2021)
    • 10.2.4 RECKITT BENCKISER GROUP PLC
    • TABLE 137 RECKITT BENCKISER GROUP PLC: BUSINESS OVERVIEW
    • FIGURE 32 RECKITT BENCKISER GROUP PLC: COMPANY SNAPSHOT (2021)
    • 10.2.5 ECOLAB
    • TABLE 138 ECOLAB: BUSINESS OVERVIEW
    • FIGURE 33 ECOLAB: COMPANY SNAPSHOT (2021)
    • 10.2.6 STERIS
    • TABLE 139 STERIS: BUSINESS OVERVIEW
    • FIGURE 34 STERIS: COMPANY SNAPSHOT (2021)
    • 10.2.7 CANTEL MEDICAL
    • TABLE 140 CANTEL MEDICAL: BUSINESS OVERVIEW
    • FIGURE 35 CANTEL MEDICAL: COMPANY SNAPSHOT (2021)
    • 10.2.8 DIVERSEY HOLDINGS LTD.
    • TABLE 141 DIVERSEY HOLDINGS LTD.: BUSINESS OVERVIEW
    • FIGURE 36 DIVERSEY HOLDINGS LTD.: COMPANY SNAPSHOT (2021)
    • 10.2.9 CARROLLCLEAN
    • TABLE 142 CARROLLCLEAN: BUSINESS OVERVIEW
    • 10.2.10 PAUL HARTMANN AG
    • TABLE 143 PAUL HARTMANN AG: BUSINESS OVERVIEW
  • *Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.

11 APPENDIX

  • 11.1 DISCUSSION GUIDE
  • 11.2 KNOWLEDGE STORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 11.3 AVAILABLE CUSTOMIZATIONS
  • 11.4 RELATED REPORTS
  • 11.5 AUTHOR DETAILS
Back to Top
전화 문의
F A Q